To hear about similar clinical trials, please enter your email below
Trial Title:
A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse
NCT ID:
NCT05732974
Condition:
Non-small Cell Lung Cancer Stage IIIA
Conditions: Official terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Conditions: Keywords:
Machine-learning
Resected early stage Non-small Cell Lung Cancer
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
Resected non small cell lung cancer
Description:
plasma sample, tissue sample and computed tomography scan images
Arm group label:
Resected early stage non small cell lung cancer
Summary:
Early-stage non small cell lung cancer represents 20-30% of all non small cell lung
cancer and is characterized by a high survival probability after surgical resection.
However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about
50% is observed, with a different survival probability on the basis of tumor node
metastasis status, although patients within the same tumor node metastasis stage exhibit
wide variations in recurrence rate. There are currently no validated prognostic
biomarkers able to identify patients with a high risk of relapse.
Detailed description:
This study will use data from an already available cohort of patients enrolled in the
Resting study (a project funded by TRANSCAN in 2018) as a training set and data from a
new concurrent cohort as validation set.
Criteria for eligibility:
Study pop:
Patient with an early stage of non small cell lung cancer with an indication of surgical
resection
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patient with an early stage of non small cell lung cancer
- Indication of surgical resection
- Patient able to understand and give his consent
- Patient affiliated to the health insurance
Exclusion Criteria:
- Patient with another cancer in the last 5 years
- Patient with an allergy to the contrast medium
- Patient under legal protection
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Julien MAZIERES
Address:
City:
Toulouse
Zip:
31059
Country:
France
Status:
Recruiting
Contact:
Last name:
Julien MAZIERES
Phone:
0567771837
Email:
mazieres.j@chu-toulouse.fr
Contact backup:
Last name:
Julie MILIA
Email:
milia.j@chu-toulouse.fr
Start date:
March 30, 2023
Completion date:
October 30, 2026
Lead sponsor:
Agency:
University Hospital, Toulouse
Agency class:
Other
Source:
University Hospital, Toulouse
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05732974
